Will PTC’s FDA Denial Interrupt Its Growth Plans?
PTC Therapeutics shares took a dive early on Monday after the company announced a key FDA decision that wasn’t good.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 192
How ContraVir Pharma Won Big on Its HBV Interim Results
ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV) is watching its shares climb on Thursday after the company reported positive interim data from its ongoing Hepatitis B (HBV) mid-stage trial. Specifically, the company announced data for CMX157,…
Top 5 Jefferies Big Pharma Stock Picks for Q4
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
Fluidigm Stumbles on Preliminary Q3 Results
After Fluidigm announced preliminary results for its third quarter on Wednesday, investors sent the shares sharply lower.
Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
IntelliPharmaCeutics Inks New Licensing Deal With Mallinckrodt
Shares of IntelliPharmaCeutics soared after the company reported a new licensing deal with Mallinckrodt.
Top Biotech Plays Highlight Jefferies Growth Stocks to Buy
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Accelerated Pharma Announces Expected Price Range for IPO
Accelerated Pharma intends to price less than 2 million shares in the range of $8 to $10 for an initial public offering valued up to more than $21 million.
Major Pharma Short Sellers Grow More Selective
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
Short Sellers Have Mixed Views on Major Biotechs
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Biostar Pharma Skyrockets on New Chinese Product Launch
Biostar Pharmaceuticals Inc. (NASDAQ: BSPM) is watching its shares nearly double on Tuesday after the company announced that it is releasing a new product line to treat respiratory irritation and inflammation. Specifically, Biostar is launching…
Nymox Wins Big on Late-Stage Trial
Nymox Pharmaceutical shares jumped following the announcement of positive results from its late-stage prostate cancer trial.
KemPharm Rises on Key FDA Approval
KemPharm shares saw a solid gain on Tuesday following a key FDA approval on it treatment for attention deficit hyperactivity disorder.
Merrimack Pharma Rises on Positive Late-Stage Results
Merrimack Pharmaceuticals shares saw a handy gain early Tuesday after the company announced positive results for its late stage metastatic pancreatic cancer study.
Illumina Stumbles Over Q3 Sales Update
When Illumina issued an update on its sales for the third quarter, the numbers came in below what analysts were looking for, and as a result investors sent the stock lower.